anti-WT1 TCR, pMP71(TCR-L126)
The vector of anti-WT1 T cell receptor (TCR) is constructed for the engineering of T cell to target Human WT1. The T cells are genetically modified through transduction with a retroviral vector expressing WT1-specific T cell receptor. And the vector product was designed for the treatment of AML, CML, MDS and in breast, colon and ovarian cancer.
Codon optimized TCR
AML, CML, MDS and in breast, colon and ovarian cancer
Human Wilms Tumor 1
WT1; WIT-2; EWS-WT1; Amino-Terminal Domain Of EWS; Last Three Zinc Fingers Of The DNA-Binding Domain Of WT1; WT33; Wilms Tumor Protein; AWT1
This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a
proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal
development of the urogenital system, and it is mutated in a small subset of patients with Wilms
tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic,
and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple
transcript variants have been described. In several variants, there is evidence for the use of a nonAUG
(CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of
PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and
that this process is tissue-restricted and developmentally regulated.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.